Search
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001)Adenine
go.drugbank.com/drugs/DB00173ApprovedInvestigationalNutraceuticalA purine base and a fundamental unit of adenine nucleotides.
Mixtures: As 3, As-3Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery … Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol.
Levocarnitine
go.drugbank.com/drugs/DB00583ApprovedInvestigationalConstituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Mixtures: Protect Cardio AFIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.
Synonyms: BORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexTopotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationaltool kit to treat such a prevalent medical condition. … [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: Bcr-Abl Tyrosine Kinase Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexStreptococcus pneumoniae type 6b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10324ApprovedInvestigationalStreptococcus pneumoniae type 6b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 6b of *Streptococcus pneumoniae* … It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Synonyms: Pneumococcal polysaccharide serotype 6B, pneumococcal capsular polysaccharide type 6B vaccineRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalThis is the subject of a clinical trial currently underway. … It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
International brands: Sheng Ao